These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 26003255)

  • 1. Lower urinary tract dysfunction in patients with multiple sclerosis.
    Panicker JN; Fowler CJ
    Handb Clin Neurol; 2015; 130():371-81. PubMed ID: 26003255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra.
    Smith CP; Nishiguchi J; O'Leary M; Yoshimura N; Chancellor MB
    Urology; 2005 Jan; 65(1):37-41. PubMed ID: 15667859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of neurogenic bladder in patients with multiple sclerosis.
    Phé V; Chartier-Kastler E; Panicker JN
    Nat Rev Urol; 2016 May; 13(5):275-88. PubMed ID: 27030526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The diagnosis and management of lower urinary tract symptoms in multiple sclerosis patients.
    Sand PK; Sand RI
    Dis Mon; 2013 Jul; 59(7):261-8. PubMed ID: 23786660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Botulinum toxin treatment for bladder dysfunction.
    Santos-Silva A; da Silva CM; Cruz F
    Int J Urol; 2013 Oct; 20(10):956-62. PubMed ID: 23634720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lower urinary tract dysfunction in Machado-Joseph disease: a study of 11 clinical-urodynamic observations.
    Sakakibara R; Uchiyama T; Arai K; Yamanishi T; Hattori T
    J Neurol Sci; 2004 Mar; 218(1-2):67-72. PubMed ID: 14759635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lower urinary tract dysfunction in MS: management in the community.
    Panicker J; Haslam C
    Br J Community Nurs; 2009 Nov; 14(11):474, 476, 478-80. PubMed ID: 20166471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Women with voiding dysfunction secondary to bladder outlet dyssynergia in the setting of multiple sclerosis do not demonstrate significantly elevated intravesical pressures.
    Lemack GE; Frohman E; Ramnarayan P
    Urology; 2007 May; 69(5):893-7. PubMed ID: 17482929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurogenic lower urinary tract dysfunction: evaluation and management.
    Tudor KI; Sakakibara R; Panicker JN
    J Neurol; 2016 Dec; 263(12):2555-2564. PubMed ID: 27401178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Onabotulinum toxin A for the treatment of neurogenic detrusor overactivity due to spinal cord injury or multiple sclerosis.
    Goessaert AS; Everaert KC
    Expert Rev Neurother; 2012 Jul; 12(7):763-75. PubMed ID: 22853784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lower urinary tract dysfunction in the neurological patient: clinical assessment and management.
    Panicker JN; Fowler CJ; Kessler TM
    Lancet Neurol; 2015 Jul; 14(7):720-32. PubMed ID: 26067125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple sclerosis produces significant changes in urinary bladder innervation which are partially reflected in the lower urinary tract functional status-sensory nerve fibers role in detrusor overactivity.
    Radziszewski P; Crayton R; Zaborski J; Członkowska A; Borkowski A; Bossowska A; Majewski M
    Mult Scler; 2009 Jul; 15(7):860-8. PubMed ID: 19542265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management and rehabilitation of neurologic patients with lower urinary tract dysfunction.
    Drake MJ
    Handb Clin Neurol; 2015; 130():451-68. PubMed ID: 26003260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic satisfaction and dissatisfaction in patients with spinal cord lesions and detrusor sphincter dyssynergia who received detrusor botulinum toxin a injection.
    Kuo HC
    Urology; 2008 Nov; 72(5):1056-60. PubMed ID: 18533231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Genital and sphincter disorders].
    Joseph PA; de Sèze M
    Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 2):1051-9. PubMed ID: 11787336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
    Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
    Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urodynamic distinctions between idiopathic detrusor overactivity and detrusor overactivity secondary to multiple sclerosis.
    Lemack GE; Frohman EM; Zimmern PE; Hawker K; Ramnarayan P
    Urology; 2006 May; 67(5):960-4. PubMed ID: 16635509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy.
    Giannantoni A; Rossi A; Mearini E; Del Zingaro M; Porena M; Berardelli A
    J Urol; 2009 Oct; 182(4):1453-7. PubMed ID: 19683298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: an objective and subjective analysis.
    Schulte-Baukloh H; Schobert J; Stolze T; Stürzebecher B; Weiss C; Knispel HH
    Neurourol Urodyn; 2006; 25(2):110-5. PubMed ID: 16470519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Urologic complications of multiple sclerosis. 180 cases].
    Amarenco G; Bosc S; Boiteau F
    Presse Med; 1996 Jun; 25(22):1007-10. PubMed ID: 8692784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.